ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luna, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luna, C. M.
Eur Respir J 2006; 27:158-164
Copyright ©ERS Journals Ltd 2006

Appropriateness and delay to initiate therapy in ventilator-associated pneumonia

C. M. Luna1, P. Aruj1, M. S. Niederman2, J. Garzón1, D. Violi1, A. Prignoni1, F. Ríos3, S. Baquero1, S. Gando1 for the Grupo Argentino de Estudio de la Neumonía Asociada al Respirador (GANAR) group

1 Pulmonary and Critical Care Divisions, Dept of Medicine, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, and 2 Critical Care Division, Policlínico Alejandro Posadas, Haedo, Provincia de Buenos Aires, Argentina. 3 Dept of Medicine and Pulmonary and Critical Care Division, Winthrop University Hospital, Mineola, NY, USA.

CORRESPONDENCE: C. M. Luna, Acevedo 1070, Banfield, 1828, Buenos Aires, Argentina. Fax: 54 1142026068. E-mail: cymluna{at}fmed.uba.ar

Keywords: Adequate therapy, antimicrobials, delayed therapy, nosocomial pneumonia, outcome, resistant pathogens

Received: April 23, 2005
Accepted August 12, 2005

Inappropriate therapy (IT) and delayed initiation of appropriate therapy (DIAT) result in inadequate therapy in patients with ventilator-associated pneumonia (VAP). The aim of the current study was to assess the impact of DIAT in VAP. A total of 76 mechanically ventilated patients with bacteriologically confirmed VAP were prospectively evaluated in the intensive care unit of six hospitals in Buenos Aires, Argentina.

Appropriate therapy was defined as coverage of all the identified pathogens by the antimicrobial therapy administered at the time of VAP clinical diagnosis. The clinical pulmonary infection score was measured during the 3 days before, at the onset and during the days which followed the onset of VAP. A total of 24 patients received adequate therapy; mortality was 29.2%. The remaining 52 patients received either IT (n = 16) or DIAT (n = 36); the mortality was 63.5% combined, and 75.0 and 58.3% for IT and DIAT, respectively (statistically significant compared with adequate therapy).

Inappropriate therapy and delayed initiation of appropriate therapy increased the mortality of ventilator-associated pneumonia. Patients with inappropriate therapy and/or delayed initiation of appropriate therapy had a more gradual increase in clinical pulmonary infection score than those receiving adequate therapy, and this increase was found to occur prior to the time of the clinical diagnosis.

In conclusion, these findings might provide the rationale for a trial of earlier initiation of therapy, based on clinical grounds in an effort to improve the outcome of patients with ventilator-associated pneumonia.




This article has been cited by other articles:


Home page
Eur Respir JHome page
H. Kothe, T. Bauer, R. Marre, N. Suttorp, T. Welte, K. Dalhoff, and the Competence Network for Community-Acquired Pneu
Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment
Eur. Respir. J., July 1, 2008; 32(1): 139 - 146.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
S. Visscher, E. M. Kruisheer, C. A. M. Schurink, P. J. F. Lucas, and M. J. M. Bonten
Predicting pathogens causing ventilator-associated pneumonia using a Bayesian network model
J. Antimicrob. Chemother., July 1, 2008; 62(1): 184 - 188.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. D. Parkins, D. M. Sabuda, S. Elsayed, and K. B. Laupland
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
J. Antimicrob. Chemother., September 1, 2007; 60(3): 613 - 618.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
D. Curcio and F. Fernandez
Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective
J. Antimicrob. Chemother., August 1, 2007; 60(2): 449 - 450.
[Full Text] [PDF]


Home page
ChestHome page
C. M. Luna, S. Baquero, S. Gando, J. R. Patron, J. G. Morato, O. Sibila, R. Absi, A. Famiglietti, C. A. Vay, F. Von Stecher, et al.
Experimental Severe Pseudomonas aeruginosa Pneumonia and Antibiotic Therapy in Piglets Receiving Mechanical Ventilation
Chest, August 1, 2007; 132(2): 523 - 531.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
D. Curcio, F. Fernandez, R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, and H. S. Sader
Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View
J. Clin. Microbiol., June 1, 2007; 45(6): 2095 - 2096.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.